Intra-tumor metabolic heterogeneity of gastric cancer on 18F-FDG PETCT indicates patient survival outcomes
The present study aimed to investigate the prognostic value of intra-tumor metabolic heterogeneity on 2-[18F] Fluoro-2-deoxy- d -glucose ( 18 F-FDG) positron emission tomography/computed tomography (PET/CT) for patients with gastric cancer. Fifty-five patients with advanced gastric cancer that had r...
Gespeichert in:
| Veröffentlicht in: | Clinical and experimental medicine 2021-02, Vol.21 (1), p.129-138 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 138 |
|---|---|
| container_issue | 1 |
| container_start_page | 129 |
| container_title | Clinical and experimental medicine |
| container_volume | 21 |
| creator | Liu, Guobing Yin, Hongyan Cheng, Xi Wang, Yan Hu, Yan Liu, Tianshu Shi, Hongcheng |
| description | The present study aimed to investigate the prognostic value of intra-tumor metabolic heterogeneity on 2-[18F] Fluoro-2-deoxy-
d
-glucose (
18
F-FDG) positron emission tomography/computed tomography (PET/CT) for patients with gastric cancer. Fifty-five patients with advanced gastric cancer that had received neoadjuvant chemotherapy and radical surgery were included. Clinicopathological information,
18
F-FDG PET/CT before chemotherapy, pathological response, recurrence or metastasis, progression-free survival (PFS), and overall survival (OS) of the patients were collected. The maximum, peak, and mean standardized uptake values (SUV
max
, SUV
peak
, and SUV
mean
), tumor-to-liver ratio (TLR), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) on PET/CT were measured. Heterogeneity index-1 (HI-1) was calculated as SUV
mean
divided by the standard deviation, and heterogeneity index-2 (HI-2) was evaluated through linear regressions of MTVs according to different SUV thresholds. Associations between these parameters and patient survival outcomes were analyzed. None of the parameters on PET were associated with tumor recurrence. Pathological responders had significantly smaller TLR, MTV and HI-2 values than non-responders (
P
= 0.017, 0.017 and 0.013, respectively). In multivariate analysis of PFS, only HI-2 was an independent factor (hazard ratio [HR] = 2.693,
P
= 0.005) after adjusting for clinical tumor-node-metastasis (TNM) stage. In multivariate analysis of OS, HI-2 was also an independent predictive factor (HR = 2.281,
P
= 0.009) after adjusting for tumor recurrence. Thus, HI-2 generated from baseline
18
F-FDG PET/CT is significantly associated with survival of patients with gastric cancer. Preoperative assessment of HI-2 by
18
F-FDG PET/CT might be promising to identify patients with poor prognosis. |
| doi_str_mv | 10.1007/s10238-020-00659-8 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2439974787</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2487005742</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2638-e8db82c5852d3078f33963662ae861866c916aa476542006d9d89610901874993</originalsourceid><addsrcrecordid>eNp9kEFr3DAQhU1JoJs0f6AnQS-9uBlJtjQ6liS7DQTaQ3IWijy79WJLW0kO5N9H6QYKOfQ0A_O9x7zXNJ85fOMA-jJzEBJbENACqN60-KFZ8d7w1vQCT952RAMfm7Oc9wC8RwmrZn8bSnJtWeaY2EzFPcZp9Ow3FUpxR4HG8szilu1cLqkevAueEouBcVy36-sN-3Vzf3XPxjCM3hXK7ODKSKGwvKSn8clNLC7Fx5nyp-Z066ZMF2_zvHlYV-2P9u7n5vbq-13rhaoZCIdHFL7HXgwSNG6lNEoqJRyh4qiUN1w512nVd6KGHcyARnEwwFF3xsjz5uvR95Din4VysfOYPU2TCxSXbEUnjdGdRl3RL-_QfVxSqN9VCjVArztRKXGkfIo5J9raQxpnl54tB_tavz3Wb2v99m_9FqtIHkW5wmFH6Z_1f1QvAwSFlg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2487005742</pqid></control><display><type>article</type><title>Intra-tumor metabolic heterogeneity of gastric cancer on 18F-FDG PETCT indicates patient survival outcomes</title><source>SpringerLink Journals - AutoHoldings</source><creator>Liu, Guobing ; Yin, Hongyan ; Cheng, Xi ; Wang, Yan ; Hu, Yan ; Liu, Tianshu ; Shi, Hongcheng</creator><creatorcontrib>Liu, Guobing ; Yin, Hongyan ; Cheng, Xi ; Wang, Yan ; Hu, Yan ; Liu, Tianshu ; Shi, Hongcheng</creatorcontrib><description>The present study aimed to investigate the prognostic value of intra-tumor metabolic heterogeneity on 2-[18F] Fluoro-2-deoxy-
d
-glucose (
18
F-FDG) positron emission tomography/computed tomography (PET/CT) for patients with gastric cancer. Fifty-five patients with advanced gastric cancer that had received neoadjuvant chemotherapy and radical surgery were included. Clinicopathological information,
18
F-FDG PET/CT before chemotherapy, pathological response, recurrence or metastasis, progression-free survival (PFS), and overall survival (OS) of the patients were collected. The maximum, peak, and mean standardized uptake values (SUV
max
, SUV
peak
, and SUV
mean
), tumor-to-liver ratio (TLR), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) on PET/CT were measured. Heterogeneity index-1 (HI-1) was calculated as SUV
mean
divided by the standard deviation, and heterogeneity index-2 (HI-2) was evaluated through linear regressions of MTVs according to different SUV thresholds. Associations between these parameters and patient survival outcomes were analyzed. None of the parameters on PET were associated with tumor recurrence. Pathological responders had significantly smaller TLR, MTV and HI-2 values than non-responders (
P
= 0.017, 0.017 and 0.013, respectively). In multivariate analysis of PFS, only HI-2 was an independent factor (hazard ratio [HR] = 2.693,
P
= 0.005) after adjusting for clinical tumor-node-metastasis (TNM) stage. In multivariate analysis of OS, HI-2 was also an independent predictive factor (HR = 2.281,
P
= 0.009) after adjusting for tumor recurrence. Thus, HI-2 generated from baseline
18
F-FDG PET/CT is significantly associated with survival of patients with gastric cancer. Preoperative assessment of HI-2 by
18
F-FDG PET/CT might be promising to identify patients with poor prognosis.</description><identifier>ISSN: 1591-8890</identifier><identifier>EISSN: 1591-9528</identifier><identifier>DOI: 10.1007/s10238-020-00659-8</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>Chemotherapy ; Computed tomography ; Gastric cancer ; Glucose ; Glycolysis ; Hematology ; Internal Medicine ; Medical prognosis ; Medicine ; Medicine & Public Health ; Metabolism ; Metastases ; Metastasis ; Multivariate analysis ; Oncology ; Original Article ; Patients ; Positron emission tomography ; Surgery ; Survival ; Tomography</subject><ispartof>Clinical and experimental medicine, 2021-02, Vol.21 (1), p.129-138</ispartof><rights>Springer Nature Switzerland AG 2020</rights><rights>Springer Nature Switzerland AG 2020.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c2638-e8db82c5852d3078f33963662ae861866c916aa476542006d9d89610901874993</citedby><cites>FETCH-LOGICAL-c2638-e8db82c5852d3078f33963662ae861866c916aa476542006d9d89610901874993</cites><orcidid>0000-0003-1922-1359</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10238-020-00659-8$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10238-020-00659-8$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids></links><search><creatorcontrib>Liu, Guobing</creatorcontrib><creatorcontrib>Yin, Hongyan</creatorcontrib><creatorcontrib>Cheng, Xi</creatorcontrib><creatorcontrib>Wang, Yan</creatorcontrib><creatorcontrib>Hu, Yan</creatorcontrib><creatorcontrib>Liu, Tianshu</creatorcontrib><creatorcontrib>Shi, Hongcheng</creatorcontrib><title>Intra-tumor metabolic heterogeneity of gastric cancer on 18F-FDG PETCT indicates patient survival outcomes</title><title>Clinical and experimental medicine</title><addtitle>Clin Exp Med</addtitle><description>The present study aimed to investigate the prognostic value of intra-tumor metabolic heterogeneity on 2-[18F] Fluoro-2-deoxy-
d
-glucose (
18
F-FDG) positron emission tomography/computed tomography (PET/CT) for patients with gastric cancer. Fifty-five patients with advanced gastric cancer that had received neoadjuvant chemotherapy and radical surgery were included. Clinicopathological information,
18
F-FDG PET/CT before chemotherapy, pathological response, recurrence or metastasis, progression-free survival (PFS), and overall survival (OS) of the patients were collected. The maximum, peak, and mean standardized uptake values (SUV
max
, SUV
peak
, and SUV
mean
), tumor-to-liver ratio (TLR), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) on PET/CT were measured. Heterogeneity index-1 (HI-1) was calculated as SUV
mean
divided by the standard deviation, and heterogeneity index-2 (HI-2) was evaluated through linear regressions of MTVs according to different SUV thresholds. Associations between these parameters and patient survival outcomes were analyzed. None of the parameters on PET were associated with tumor recurrence. Pathological responders had significantly smaller TLR, MTV and HI-2 values than non-responders (
P
= 0.017, 0.017 and 0.013, respectively). In multivariate analysis of PFS, only HI-2 was an independent factor (hazard ratio [HR] = 2.693,
P
= 0.005) after adjusting for clinical tumor-node-metastasis (TNM) stage. In multivariate analysis of OS, HI-2 was also an independent predictive factor (HR = 2.281,
P
= 0.009) after adjusting for tumor recurrence. Thus, HI-2 generated from baseline
18
F-FDG PET/CT is significantly associated with survival of patients with gastric cancer. Preoperative assessment of HI-2 by
18
F-FDG PET/CT might be promising to identify patients with poor prognosis.</description><subject>Chemotherapy</subject><subject>Computed tomography</subject><subject>Gastric cancer</subject><subject>Glucose</subject><subject>Glycolysis</subject><subject>Hematology</subject><subject>Internal Medicine</subject><subject>Medical prognosis</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Metabolism</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>Multivariate analysis</subject><subject>Oncology</subject><subject>Original Article</subject><subject>Patients</subject><subject>Positron emission tomography</subject><subject>Surgery</subject><subject>Survival</subject><subject>Tomography</subject><issn>1591-8890</issn><issn>1591-9528</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNp9kEFr3DAQhU1JoJs0f6AnQS-9uBlJtjQ6liS7DQTaQ3IWijy79WJLW0kO5N9H6QYKOfQ0A_O9x7zXNJ85fOMA-jJzEBJbENACqN60-KFZ8d7w1vQCT952RAMfm7Oc9wC8RwmrZn8bSnJtWeaY2EzFPcZp9Ow3FUpxR4HG8szilu1cLqkevAueEouBcVy36-sN-3Vzf3XPxjCM3hXK7ODKSKGwvKSn8clNLC7Fx5nyp-Z066ZMF2_zvHlYV-2P9u7n5vbq-13rhaoZCIdHFL7HXgwSNG6lNEoqJRyh4qiUN1w512nVd6KGHcyARnEwwFF3xsjz5uvR95Din4VysfOYPU2TCxSXbEUnjdGdRl3RL-_QfVxSqN9VCjVArztRKXGkfIo5J9raQxpnl54tB_tavz3Wb2v99m_9FqtIHkW5wmFH6Z_1f1QvAwSFlg</recordid><startdate>20210201</startdate><enddate>20210201</enddate><creator>Liu, Guobing</creator><creator>Yin, Hongyan</creator><creator>Cheng, Xi</creator><creator>Wang, Yan</creator><creator>Hu, Yan</creator><creator>Liu, Tianshu</creator><creator>Shi, Hongcheng</creator><general>Springer International Publishing</general><general>Springer Nature B.V</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TK</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-1922-1359</orcidid></search><sort><creationdate>20210201</creationdate><title>Intra-tumor metabolic heterogeneity of gastric cancer on 18F-FDG PETCT indicates patient survival outcomes</title><author>Liu, Guobing ; Yin, Hongyan ; Cheng, Xi ; Wang, Yan ; Hu, Yan ; Liu, Tianshu ; Shi, Hongcheng</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2638-e8db82c5852d3078f33963662ae861866c916aa476542006d9d89610901874993</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Chemotherapy</topic><topic>Computed tomography</topic><topic>Gastric cancer</topic><topic>Glucose</topic><topic>Glycolysis</topic><topic>Hematology</topic><topic>Internal Medicine</topic><topic>Medical prognosis</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Metabolism</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>Multivariate analysis</topic><topic>Oncology</topic><topic>Original Article</topic><topic>Patients</topic><topic>Positron emission tomography</topic><topic>Surgery</topic><topic>Survival</topic><topic>Tomography</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Liu, Guobing</creatorcontrib><creatorcontrib>Yin, Hongyan</creatorcontrib><creatorcontrib>Cheng, Xi</creatorcontrib><creatorcontrib>Wang, Yan</creatorcontrib><creatorcontrib>Hu, Yan</creatorcontrib><creatorcontrib>Liu, Tianshu</creatorcontrib><creatorcontrib>Shi, Hongcheng</creatorcontrib><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical and experimental medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Liu, Guobing</au><au>Yin, Hongyan</au><au>Cheng, Xi</au><au>Wang, Yan</au><au>Hu, Yan</au><au>Liu, Tianshu</au><au>Shi, Hongcheng</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Intra-tumor metabolic heterogeneity of gastric cancer on 18F-FDG PETCT indicates patient survival outcomes</atitle><jtitle>Clinical and experimental medicine</jtitle><stitle>Clin Exp Med</stitle><date>2021-02-01</date><risdate>2021</risdate><volume>21</volume><issue>1</issue><spage>129</spage><epage>138</epage><pages>129-138</pages><issn>1591-8890</issn><eissn>1591-9528</eissn><abstract>The present study aimed to investigate the prognostic value of intra-tumor metabolic heterogeneity on 2-[18F] Fluoro-2-deoxy-
d
-glucose (
18
F-FDG) positron emission tomography/computed tomography (PET/CT) for patients with gastric cancer. Fifty-five patients with advanced gastric cancer that had received neoadjuvant chemotherapy and radical surgery were included. Clinicopathological information,
18
F-FDG PET/CT before chemotherapy, pathological response, recurrence or metastasis, progression-free survival (PFS), and overall survival (OS) of the patients were collected. The maximum, peak, and mean standardized uptake values (SUV
max
, SUV
peak
, and SUV
mean
), tumor-to-liver ratio (TLR), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) on PET/CT were measured. Heterogeneity index-1 (HI-1) was calculated as SUV
mean
divided by the standard deviation, and heterogeneity index-2 (HI-2) was evaluated through linear regressions of MTVs according to different SUV thresholds. Associations between these parameters and patient survival outcomes were analyzed. None of the parameters on PET were associated with tumor recurrence. Pathological responders had significantly smaller TLR, MTV and HI-2 values than non-responders (
P
= 0.017, 0.017 and 0.013, respectively). In multivariate analysis of PFS, only HI-2 was an independent factor (hazard ratio [HR] = 2.693,
P
= 0.005) after adjusting for clinical tumor-node-metastasis (TNM) stage. In multivariate analysis of OS, HI-2 was also an independent predictive factor (HR = 2.281,
P
= 0.009) after adjusting for tumor recurrence. Thus, HI-2 generated from baseline
18
F-FDG PET/CT is significantly associated with survival of patients with gastric cancer. Preoperative assessment of HI-2 by
18
F-FDG PET/CT might be promising to identify patients with poor prognosis.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><doi>10.1007/s10238-020-00659-8</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0003-1922-1359</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1591-8890 |
| ispartof | Clinical and experimental medicine, 2021-02, Vol.21 (1), p.129-138 |
| issn | 1591-8890 1591-9528 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2439974787 |
| source | SpringerLink Journals - AutoHoldings |
| subjects | Chemotherapy Computed tomography Gastric cancer Glucose Glycolysis Hematology Internal Medicine Medical prognosis Medicine Medicine & Public Health Metabolism Metastases Metastasis Multivariate analysis Oncology Original Article Patients Positron emission tomography Surgery Survival Tomography |
| title | Intra-tumor metabolic heterogeneity of gastric cancer on 18F-FDG PETCT indicates patient survival outcomes |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T01%3A05%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Intra-tumor%20metabolic%20heterogeneity%20of%20gastric%20cancer%20on%2018F-FDG%20PETCT%20indicates%20patient%20survival%20outcomes&rft.jtitle=Clinical%20and%20experimental%20medicine&rft.au=Liu,%20Guobing&rft.date=2021-02-01&rft.volume=21&rft.issue=1&rft.spage=129&rft.epage=138&rft.pages=129-138&rft.issn=1591-8890&rft.eissn=1591-9528&rft_id=info:doi/10.1007/s10238-020-00659-8&rft_dat=%3Cproquest_cross%3E2487005742%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2487005742&rft_id=info:pmid/&rfr_iscdi=true |